Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development".